General
Preferred name
BREXPIPRAZOLE
Synonyms
OPC-34712 ()
BREXPIPRAZOL ()
REXULTI ()
Rxulti ()
Brexpiprazole HCl ()
Brexpiprazole-d8 ()
P&D ID
PD009042
CAS
913611-97-9
913612-38-1
1427049-21-5
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2015
Drug indication
Psychosis
Major depressive disorder
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) .
(GtoPdb)
DESCRIPTION
Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic ¦Á1B (Ki=0.17 nM) and ¦Á2C receptors (Ki=0.59 nM)[1][2].
PRICE
56
PRICE
412
DESCRIPTION
Brexpiprazole HCl (OPC 34712 dihydrochloride) is a new antipsychotic drug.
DESCRIPTION
Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is used as an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
(Enamine Bioactive Compounds)
DESCRIPTION
Brexpiprazole (OPC-34712) is a partial agonist of human 5-hydroxytryptamine (5-HT) 5-HT1A and dopamine D2 receptors.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
22
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Other bioactive compounds
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
156
Molecular Weight
433.18
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
4.72
TPSA
48.57
Fraction CSP3
0.32
Chiral centers
0.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT1A
5-HT2A
D2L
dopamine
α1B-adrenergic receptor
α2C receptors
DRD2
Adrenergic Receptor
Dopamine Receptor
Indication
depression, schizophrenia
MOA
dopamine receptor partial agonist
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Recommended Cell Concentration
None
Source data

